Login to Your Account



Clinic Roundup


Monday, October 15, 2012
• Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., said updated data from its Phase II trial of oral sapacitabine in older patients with intermediate-2 or high-risk myelodysplastic syndromes after treatment failure with front-line hypomethylating agents such as Vidaza (azacitadine, Celgene Corp.) and/or Dacogen (decitabine, Astex Pharmaceuticals Inc.) showed a median overall survival rate to date for all 63 patients of 252 days, or about eight months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription